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Vessel sprouting by endothelial cells (ECs) during angio-
genesis relies on a navigating tip cell and on proliferating
stalk cells that elongate the shaft. To date, only genetic
signals have been shown to regulate vessel sprouting.
However, emerging evidence indicates that the angio-
genic switch also requires a metabolic switch. Indeed,
angiogenic signals not only induce a change in EC me-
tabolism but this metabolic adaptation also co-deter-
mines vessel sprouting. The glycolytic activator PFKFB3
regulates stalk cell proliferation and renders ECs more
competitive to reach the tip. We discuss the emerging
link between angiogenesis and EC metabolism during
the various stages of vessel sprouting, focusing only on
genetic signals for which an effect on EC metabolism has
been documented.
Model of vessel sprouting
Blood vessels rapidly switch from a state of quiescence to
active sprouting in response to pro-angiogenic stimuli.
Specific EC subtypes orchestrate vessel sprouting. Navi-
gating tip cells (see Glossary) lead the vessel branch at the
vascular forefront, while proliferating stalk cells elongate
the shaft in the new sprout [1]. Neighboring sprouts anas-
tomose through interactions between filopodia on their
respective tip cells to form a new and perfused vessel
branch. ECs then regain their quiescent state (phalanx
cells) and are stabilized by the coverage of perivascular
mural pericytes [2]. Instead of providing a complete survey
of all known genetic molecules known to regulate vessel
sprouting (for which we refer to more historical overviews
[3–6]), we limit our overview here to molecules with known
effects on EC metabolism. We first describe the metabolic
pathways that ECs use to generate energy.
Energy generation in ECs
Glucose metabolism
In contrast to other healthy cells [7,8], ECs rely heavily
on glycolysis to generate energy (Figure 1) [8–10]. The
glycolysis rate in ECs is comparable to the rate measured
in various tumor cells [8]. Glycolysis is essential for ECs to
maintain homeostasis because nearly complete inhibition
of glycolysis with the glycolysis inhibitor 2-deoxy-D-glu-
cose (2-DG) induces cell death [8]. Notably, ECs rely mini-
mally on glucose oxidation and mitochondrial respiration
for ATP production [8,10]. Nonetheless, mitochondria rep-
resent a bioenergetic reserve to which ECs appeal under
stressed conditions [11].
Upon induction of sprouting by growth factors such
as vascular endothelial growth factor (VEGF), quiescent
Review
Glossary
Anastomosis: the process in which a tip cell meets and fuses with another tip
cell or a pre-existing blood vessel to form a lumenized loop that allows blood
flow.
Filopodia: thin (0.1–0.3 mm) long (10 mm) finger-like actin-rich plasma mem-
brane protrusions composed of parallel bundles of filamentous actin important
in cell migration, adhesion to the extracellular matrix, guidance towards
chemoattractants, cell–cell signaling, embryonic development, and wound
healing.
Glycocalyx: an interconnected gel-like network of membrane-bound proteo-
glycans and glycoproteins coating the luminal surface of ECs. This layer is
involved in the mechano-transduction of shear stress, the adherence of blood
cells, vascular permeability, and vessel wall homeostasis.
Glycolysis: the breakdown of glucose to pyruvate in 10 consecutive
cytoplasmic reactions to generate energy (ATP) and reducing power (NADH).
Hexosamine biosynthesis pathway (HBP): the metabolic pathway of which the
rate-limiting step is the transfer of the glutamine amido group to fructose-6-
phosphate. Ultimately, glucosamine-6-phosphate, the key precursor for O- and
N-linked protein glycosylation, is generated.
Lamellipodia: thin (0.1–0.2 mm) sheet-like protrusions behind the protruding
cell edge consisting of a densely branched filamentous actin network and that
are important in cell migration, substrate adhesion, macropinocytosis, and
phagocytosis.
Pentose phosphate pathway (PPP): the metabolic pathway that converts
glucose-6-phosphate to ribose-5-phosphate, a key intermediate of nucleotide
synthesis, with production of NADPH, and is important for several anabolic
processes and redox homeostasis.
Pericytes: (peri, around; cyte, cell) mural cells that cover blood microvessels
and share the vascular basement membrane. They provide support, ensure
vessel stability, and regulate permeability by direct physical contact and
paracrine signaling with ECs.
Phalanx cells: specialized ECs that are quiescent, lack filopodia, and are aligned
in a smooth tight cobblestone monolayer to ensure optimal blood flow and
stable perfusion of the surrounding tissues.
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3): a key reg-
ulatory bifunctional enzyme of the glycolytic flux. It has a high kinase:pho-
sphatase ratio (!740:1) and as such generates high amounts of fructose-2,6-
bisphosphate, the most potent allosteric activator of the rate-limiting glycolytic
enzyme phosphofructokinase-1 (PFK-1).
Spheroid assay: the use of in vitro established 3D EC aggregates to study EC
sprouting.
Stalk cells: specialized ECs that form the stalk of vascular sprouts. Stalk cells
trail behind tip cells, proliferate to elongate the stalk, and form a lumen. They
also prevent retraction of ECs.
Tip cells: specialized ECs located at the tip of the vascular sprout. These cells
are highly polarized, extend numerous filo- and lamellipodia with which they
probe the environment, and are key to both anastomosis and migration
because they direct the sprout.
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ECs increase their glycolysis rate by upregulating the
expression of, amongst others, glucose transporter 1
(GLUT-1: facilitates the transport of glucose across the
plasma membrane), lactate dehydrogenase-A (LDH-A:
converts pyruvate and NADH to L-lactate and NAD+),
and 6-phosphofructo-2-kinase/fructose-2,6-bisphospha-
tase-3 (PFKFB3) [8,9,12,13]. PFKFB3 synthesizes fruc-
tose-2,6-bisphosphate (F2,6P2), an allosteric activator of
phosphofructokinase-1 (PFK-1) and the most potent stimu-
lator of glycolysis [14]. Reducing glycolysis by PFKFB3 gene
silencing in ECs in vitro decreases EC migration and prolif-
eration, and impairs vessel sprouting in EC spheroid assays.
Furthermore, PFKFB3 gene inactivation in ECs in vivo
impedes vessel sprouting, branching, and outgrowth [8].
In view of the exposure of ECs to oxygen in the blood, the
importance of glycolysis in ECs might seem paradoxical
given that oxidative phosphorylation (OXPHOS) is more
efficient in generating ATP (approximately 20-fold more
ATP per glucose molecule [15]). However, this preference
can be explained by several reasons. First, endothelial
oxygen consumption would decrease the availability for
trans-endothelial transport to perivascular cells. Second,
the low oxygen-dependence of ECs might prepare them for
sprouting in hypoxic tissues. As such, ECs are able to
quickly sprout without the need to adapt to fluctuating
oxygen levels. This is further strengthened by the fact that
oxygen is more limiting than glucose in the tumor inter-
stitium (compared to glucose, oxygen has a higher diffu-
sion coefficient, but lower solubility and therefore also
lower available tissue concentration, resulting in a shorter
diffusion distance and steeper concentration gradient
from the vessel to the tissue [16–18]), and because ECs
are only susceptible to hypoxia when glucose is limiting
[19]. Third, lower oxidative metabolism results in less
oxidative stress. Fourth, when glucose availability is un-
limited, the glucose uptake and glycolysis rates can be
elevated to equal or even exceed the ATP production by
OXPHOS [10,15]. Finally, to sustain cell division and
migration, glycolysis intermediates can be shunted to
side-branches such as the pentose phosphate pathway
(PPP) and the hexosamine biosynthetic pathway (HBP).
The PPP is essential for nucleotide, lipid, and aromatic
amino acid synthesis as well as for anti-oxidant protection,
whereas the HBP is considered a nutrient sensor impor-
tant in protein glycosylation (Figure 1). The first and rate-
limiting step of the oxidative part of the PPP (oxPPP) is
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Figure 1. Endothelial cell (EC) metabolism. Schematic overview of the principal metabolic pathways and key enzymes in ECs. Glucose is taken up via the GLUT-1
transporter and subsequently phosphorylated by hexokinase. Quiescent ECs mainly rely on glycolysis to generate the energy needed to perform their functions, whereas
sprouting ECs even further upregulate their glycolysis rate. Glycolysis intermediates are shunted into side-branches for anti-oxidant defense and lipid synthesis (oxPPP) as
well as nucleotide synthesis (both oxPPP and non-oxPPP) and glycosylation purposes (HBP). Upon glucose scarcity, intracellular reserves can be broken down to sustain the
rate of glycolysis. ECs also use FAs and glutamine as energy sources via FAO and glutaminolysis respectively. The latter is required to maintain the functionality of the TCA
cycle (anaplerosis) as TCA cycle intermediates (e.g., citrate) exit for anabolic purposes. Abbreviations: 2-DG, 2-deoxy-D-glucose; DHAP, dihydroxyacetone phosphate;
F1,6P2, fructose-1,6-bisphosphate; F2,6P2, fructose-2,6-bisphosphate; F6P, fructose-6-phosphate; FABP4, fatty acid binding protein 4; FAs, fatty acids; FAO, fatty acid
oxidation; G1P, glucose-1-phosphate; G3P, glyceraldehyde-3-phosphate; G6P, glucose-6-phosphate; G6PDH, G6P dehydrogenase; GLS, glutaminase; Gln, glutamine; Glu,
glutamate; GlucN6P, glucosamine-6-phosphate; GLUT-1, glucose transporter 1; GlyP, glycogen phosphorylase; HBP, hexosamine biosynthetic pathway; HK, hexokinase; a-
KG, a-ketoglutarate; LDH-A, lactate dehydrogenase A; NADPH, nicotinamide adenine dinucleotide phosphate; (non-)oxPPP, (non-)oxidative branch of the pentose
phosphate pathway; OXPHOS, oxidative phosphorylation; 6-PG, 6-phosphogluconate; 6-PGL, 6-phosphogluconolactone; PFK-1, phosphofructokinase-1; PFKFB3, 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3; Pyr, pyruvate; R5P, ribulose-5-phosphate; TA, transaldolase; TCA, tricarboxylic acid; TKT, transketolase; UDP-
GlcNAc, uridine diphosphate N-acetylglucosamine.
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catalyzed by glucose-6-phosphate (G6P) dehydrogenase
(G6PDH), the plasma membrane localization and activity
of which is regulated by Src-mediated tyrosine phosphor-
ylation, and which plays a role in VEGF-mediated phos-
phorylation of Akt, VEGFR2, and eNOS, and EC responses
such as migration, proliferation, and tube formation
[20,21]. This is exemplified by a decrease in EC viability
and migration upon G6PDH inhibition by either a phar-
macological compound [22] or by high glucose levels [23].
Inhibition of transketolase, an enzyme involved in the non-
oxidative part of the PPP (non-oxPPP), also reduces EC
viability and migration [22]. Interestingly, inhibition of the
non-oxPPP has a more pronounced effect on EC viability
and migration than inhibition of the oxPPP, suggesting
that the reversible non-oxPPP compensates for the reduced
nucleotide synthesis via the oxPPP [22]. However, it is
worth mentioning that the relative importance of the
oxPPP in vitro might have been underestimated because
of the high glucose concentrations used in many studies,
which can suppress this branch [23]. Hence, both arms may
be important, but in different metabolic contexts.
Cells store energy in glycogen reservoirs that can be
used when extracellular glucose levels are insufficient to
meet the energy demand (Figure 1). VEGF signaling and
glucose deprivation induce glycogenolysis, which is the
breakdown of glycogen to G6P in ECs [22]. Further, phar-
macological inhibition of glycogen phosphorylase (and thus
of glycogenolysis) reduces EC viability and migration [22].
Although glycogenolysis-derived G6P only has a limited
contribution to glycolysis and energy production [24], it
may have more importance in glycolysis side-branches
such as the oxPPP. This has recently been shown to be
the case for tumor cells [25], but similar evidence in ECs is
still lacking. Overall, it is not yet clear which role glycogen
has in vascular sprouting.
Other metabolic pathways
In addition to glucose, ECs also use glutamine and fatty
acids as fuels (Figure 1). ECs are well-equipped to take up
and metabolize glutamine [26,27], a conditionally essential
amino acid [28]. Glutaminase catalyzes the conversion of
glutamine to glutamate, the first step of glutaminolysis
that yields a-ketoglutarate. The latter is used in the tri-
carboxylic acid (TCA) cycle to replace TCA cycle intermedi-
ates that have exited for anabolic purposes, thus
sustaining the functionality of the TCA cycle (anaplerosis)
[28]. In addition, glutamine is a key nitrogen source [28]
and contributes to improved viability of ECs under oxida-
tive stress [29]. The glutaminase activity of ECs has been
reported to be high [10] and its inhibition induces EC
senescence [30].
ECs can also obtain energy via the oxidation of fatty
acids from intra- and extracellular sources [31] (Figure 1).
Endothelial fatty acid oxidation (FAO) is increased in vitro
upon glucose deprivation through activation of AMP-acti-
vated protein kinase (AMPK), and upon stimulation with
carnitine [31] which is required for mitochondrial import of
fatty acids. VEGF-B is a poor angiogenic factor with rela-
tively restricted activity on coronary vessels, but VEGF-B
signaling via VEGF receptor 1 (VEGFR1)/neuropilin 1
increases the uptake and trans-endothelial transport of
fatty acids in ECs [32], but without influencing FAO in ECs
[33]. VEGF induces the expression levels of fatty acid
binding protein 4 (FABP4). This protein is involved in
uptake and trafficking of intracellular fatty acids, and
knockdown of FABP4 reduces EC proliferation [34], indi-
cating the importance of lipid metabolism.
Sprouting in a metabolically taxing environment: tip
versus stalk cells
Genetic signals
In response to hypoxia, the key angiogenic signal VEGF is
secreted in an attempt to restore tissue oxygenation by
promoting vessel sprouting. When VEGF reaches the vas-
cular front it binds to VEGF receptor 2 (VEGFR2) on ECs.
The EC exposed to the highest level of VEGF is selected to
become a tip cell. The current model of vascular branching
is based on the coordinated actions of migrating tip cells,
taking the lead at the vascular front, and proliferating
stalk cells elongating the newly developing branch [1], with
the fate of both cell types being dynamically interchange-
able rather than being permanently fixed [35] (Figure 2A).
The specification of tip versus stalk cells is dictated by
VEGF–Notch signaling. VEGFR2-activated tip cells ex-
press the Notch ligand Delta-like 4 (Dll4), which binds
to Notch receptors (single-pass transmembrane receptor
proteins) in neighboring ECs. This results in the release of
the receptor intracellular domain from the membrane,
Notch intracellular domain (NICD), which translocates
to the nucleus and regulates transcription of target genes
[36]. As a result, VEGFR2 expression is lowered whereas
levels of the VEGF trap VEGFR1 increase, which renders
ECs less responsive to VEGF, thus out-competing their
ability to become a tip cell and promoting a stalk cell fate
(Figure 2A). Dynamic tip cell–stalk cell fate interchange or
‘cell shuffling’ occurs at the vascular front to allow the ECs
with the highest VEGFR2 and lowest VEGFR1 expression
levels to occupy the tip position to ensure maximal fitness
of leading the sprout [35,37]. There are many more mole-
cules regulating tip versus stalk cell behavior, such as for
instance VEGF-C/VEGFR3, the angiopoietins, the TGF-b/
BMP9 receptor, and others [1], but these signals are not
known to affect EC metabolism in physiological conditions.
Metabolic signals
Recent findings indicate that VEGF increases glycolysis in
ECs by upregulating PFKFB3 mRNA and protein levels
before ECs start to proliferate, whereas Dll4-induced pro-
stalk Notch signaling induces the opposite effect [8], im-
plying that tip cells have higher glycolysis rates
(Figure 2B). Nonetheless, glycolysis is also essential for
stalk cell functions. Stalk cells actively proliferate and
therefore must generate high amounts of ATP and macro-
molecules that are derived from metabolic pathways, such
as the PPP, that branch off from the main glycolytic
pathway [7] (Figure 2C). However, Notch inhibits EC
proliferation in vitro. Hence, the growth-inhibitory func-
tion of Notch signaling must be overridden in vivo. Indeed,
Notch in stalk cells induces the expression of the Notch-
regulated ankyrin repeat protein (Nrarp), which in turn
enhances Wnt signaling to promote stalk cell proliferation
and vessel stability [38].
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Remarkably, overexpression of PFKFB3 overcomes
the pro-stalk activity of Notch signaling and promotes
stalk cells to adopt a tip cell behavior, both in EC
spheroid sprouting assays in vitro and in zebrafish vas-
cular branching in vivo, whereas silencing of PFKFB3
causes opposite effects in baseline conditions and upon
inhibition of Notch signaling [8]. These findings are
intriguing because no other genetic signal is so far
known to be able to overrule the pro-stalk activity of
Notch. Notably, over- or underexpression of PFKFB3 in
baseline conditions or in conditions favoring tip cell
behavior (upon inhibition of Notch signaling), or stalk
cell behavior (upon activation of Notch signaling), did not
alter the molecular signature of genes enriched in either
tip or stalk cells, indicating that PFKFB3 did not affect
tip and stalk cells through regulation of tip/stalk cell
signals [8]. Instead, these studies show for the first time
that metabolism (in this case, PFKFB3-driven glycolysis)
controls vessel branching in parallel to genetic signals
(Figure 3).
The metabolic status of the milieu into which new
vessels branch out complements the above mechanisms
via a feedback loop involving the NAD+-dependent deace-
tylase Sirtuin 1 (SIRT1). Upon sensing energy/fuel stress,
SIRT1 activity increases to deacetylate and to pre-destine
NICD for proteasomal degradation [39] (Figure 2A). These
findings might imply that the subsequent lowering of the
Notch-driven pro-stalk activity allows SIRT1 to direct tip
cells towards fuel-rich areas. Conversely, ECs with re-
duced SIRT1 activity fail to sense nutrient stress ade-
quately and are sensitized to pro-stalk Notch signaling,
resulting in impaired vessel growth [40].
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Figure 2. Genetic and metabolic determinants of tip, stalk and phalanx cell behavior. (A) Schematic representation of a vascular sprout with tip cell (green), stalk cell (blue)
and phalanx cell (yellow) and key genetic fate-determining factors. Upon sensing a VEGF gradient (red background) the tip cell induces Dll4 expression to activate Notch
signaling in the adjacent stalk cells (NICD release) and subsequently to decrease VEGFR2 and increase VEGFR1 levels to reduce VEGF sensitivity. SIRT1 translates energy
stress into NICD degradation resulting in tip cell behavior. (B–D) Different types of metabolism characterize the different EC subtypes; unknown metabolic changes are
indicated by question marks. For their migratory behavior, tip cells require large amounts of ATP. These are generated primarily by the high glycolytic flux (B). Stalk cells
divide to elongate the newly formed sprout and consequently require building blocks for rapid macromolecular synthesis. To obtain these precursors, NADPH is generated
in the oxPPP, nucleotides are synthesized via the non-oxPPP and/or oxPPP, and fatty acids and ATP are obtained by combining glycolysis and likely also anapleurotic
glutaminolysis (C). Phalanx cell metabolism ensures cellular homeostasis and provides energy for vital functions (D). Abbreviations: Dll4, Delta-like 4; FAO, fatty acid
oxidation; G6P, glucose-6-phosphate; Gln, glutamine; HBP, hexosamine biosynthetic pathway; NADPH, nicotinamide adenine dinucleotide phosphate; NICD, Notch
intracellular domain; (non-)oxPPP, (non-)oxidative branch of the pentose phosphate pathway; Pyr, pyruvate; SIRT1, Sirtuin1; TCA, tricarboxylic acid; VEGF, vascular
endothelial growth factor; VEGFR, VEGF receptor.
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The HBP pathway is another nutrient sensing pathway.
Inhibition of this pathway by 2-DG impedes angiogenesis,
which can be rescued by the N-linked glycosylation pre-
cursor mannose [41]. It is therefore tempting to speculate
that the HBP in ECs serves to translate nutrient stress
into adjusting blood vessel supply by generating N-acetyl-
glucosamine that post-translationally modifies and acti-
vates key angiogenic receptors. Indeed, VEGFR2 function
requires N-glycosylation [42]. Also noteworthy is the evi-
dence that the Notch response to the ligands Dll4 and
Jagged1 depends on the level of glycosylation of its extra-
cellular domain [43].
Metabolites can also control angiogenesis by acting as
bona fide signaling molecules. An example is the glycolysis
product lactate, which is taken up by ECs via the mono-
carboxylate transporter 1 (MCT1), and which mainly has a
signaling role because it seems to be only marginally
metabolized [44], at least at normal extracellular glucose
levels [24]. Once taken up by ECs, lactate competitively
inhibits the oxygen-sensing prolyl hydroxylase domain
protein 2 (PHD2), resulting in activation of hypoxia-induc-
ible factor 1a (HIF-1a) and a secondary increase in
VEGFR2 and basic fibroblast growth factor expression
[45]. PHD2 inhibition by lactate also triggers IkBa degra-
dation, releasing the transcription factor NF-kB to induce
the expression of the pro-angiogenic interleukin-8 [44].
Lactate also engages the PI3K/Akt pathway via upregula-
tion of the ligands and subsequent activation of three
receptor tyrosine kinases: Axl, the angiopoietin receptor
Tie2, and VEGFR2 [46]. Moreover, lactate signaling
induces VEGF expression [47] and reduces post-transla-
tional poly-ADP ribosylation of VEGF, thereby making it
more potent [48]. Lactate also promotes collagen and
proteoglycan matrix deposition [49], and stimulates EC
migration and capillary tube formation [44,49], although it
remains to be defined if matrix deposition induced by
lactate is causally linked to vessel sprouting. Finally,
lactate induces pro-angiogenic reactive oxygen species in
ECs [44].
Compartmentalization of glycolysis in F-actin-rich
lamellipodia
In ECs, both filopodia and lamellipodia have typical actin
networks (branched actin for lamellipodia versus aligned
filamentous actin for filopodia) that can be assembled within
minutes after growth factor stimulation [50]. The highly
dynamic nature of these structures relies on active actin
cytoskeleton remodeling and requires rapid generation and
instantaneous availability of large amounts of ATP; actin
polymerization for example is tightly linked to ATP hydro-
lysis [51–53]. Nevertheless, both filopodia and lamellipodia
are devoid of mitochondria [8], likely because mitochondria
(ranging in size from 0.5 to over 4 mm) cannot spatially fit
into the narrow filopodia and lamellipodia (!250 nm wide
and high, respectively) [54] (Figure 4A,C,D).
It is unlikely that sufficient amounts of ATP reach the
very tip of the filopodia (up to 10 mm in length) sufficiently
fast by diffusion from the distant perinuclear mitochondri-
al network; but, even so, it is conceivable that the continu-
ous protrusion and retraction of filopodia and lamellipodia
locally generates such a high ATP demand that ATP levels
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Figure 3. Metabolic switching between tip and stalk cells. (A) Metabolic glycolytic
signature of tip cells: tip cells are known to have high VEGF/VEGFR2 signaling.
Activation of VEGFR2 by VEGF upregulates PFKFB3 levels. PFKFB3 produces F2,6P2,
which is the most potent stimulator of PFK-1, a rate-limiting enzyme of the glycolytic
pathway. Consequently, the glycolysis rate is elevated which renders ECs more
competitive to reach the tip. By contrast, Dll4/Notch signaling, releasing NICD,
reduces glycolysis by lowering PFKFB3 expression, but this signaling pathway is less
active in tip cells. (B) Metabolic glycolytic signature of stalk cells: stalk cells are known
to have high Dll4/Notch signaling. Activation of Notch by Dll4 lowers PFKFB3-driven
glycolysis, thereby reducing competitiveness for the tip position. (C) Overexpression
of PFKFB3 induces switching from the stalk to the tip cell phenotype: Overexpression
of PFKFB3 in ECs, instructed to adopt a stalk cell phenotype by overexpression of
NICD, is capable of overcoming the stalk cell phenotype and increasing
the competitiveness of these cells for the tip position. Abbreviations: Dll4, Delta-
like 4; F2,6P2, fructose-2,6-bisphosphate; F6P, fructose-6-phosphate; NICD, Notch
intracellular domain; PFK-1, phosphofructokinase-1; PFKFB3, 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase-3; PFKFB3-OE, PFKFB3-overexpressing; VEGF,
vascular endothelial growth factor; VEGFR2, VEGF receptor 2 (the question mark
indicates that VEGFR2 probably mediates the VEGF response, but this needs to be
proven in the future).
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throughout the whole cell body might become compromised
during active lamellipodial and filopodial activity. To avoid
this, ECs compartmentalize glycolysis with the actin skel-
eton in cellular protrusions, mediating EC motility [8].
Various glycolytic enzymes contain actin-binding sites,
and binding to F-actin enhances their activity [55]. In
migrating ECs, both PFKFB3 and other glycolytic enzymes
– such as phosphoglycerate kinase and the pyruvate kinase
isoenzyme that generates ATP (PK-M1), rather than the
isoenzyme involved in biosynthesis of macromolecules
(PK-M2) – are enriched in the membrane ruffles at the
leading front of lamellipodia, and co-concentrate with F-
actin in these structures [8] (Figure 4B–D). Co-immuno-
precipitation experiments confirmed the PFKFB3-actin
interaction and showed that the fraction of PFKFB3 bound
to actin increases during EC motility [8]. Localizing glycol-
ysis-driven ATP production at the site of high ATP demand
during motility prevents the cell from succumbing to over-
all ATP depletion. Of note, compartmentalization of gly-
colysis in motile structures originated early in evolution:
for example, flagella in various microorganisms and ten-
tacles on members of the basal metazoan Hydra genus
[56,57]. Noteworthy in this respect, astrocytes localize
glycogen depots in their lamellipodial and filopodial exten-
sions, and glycolysis and glycogenolysis are essential for
astrocytic responses to increasing energy demand [58].
Phalanx cells: quiescent again
Genetic signals
ECs resume a quiescent state once the new vessel branch is
formed, and then adopt a cobblestone-like appearance that
resembles the ancient Greek military phalanx formation –
hence the term ‘phalanx cells’ [59]. These cells have few
filopodia, are non-proliferating, survive for years, migrate
poorly, and have an attenuated response to VEGF. Pha-
lanx cells express elevated levels of VEGFR1 to diminish
the pro-angiogenic signaling of VEGF [59] (Figure 2A).
Elevated signaling through Notch and the Tie2 receptor
in response to elevated levels of angiopoietin-1 between
ECs in trans additionally promotes EC quiescence [60,61].
Phalanx cells form a tight barrier and their monolayer
apposition allows conduction of blood flow, which by itself
is an important regulator of EC quiescence [1]. Vessel
stabilization is further enhanced by the deposition of a
basement membrane (BM) around quiescent ECs; this is in
part due to the fact that the BM component laminin a4
reduces tip cell specification by inducing Notch signaling
[62,63]. The expression of vascular endothelial cadherin
(VE-cadherin) and neuronal cadherin (N-cadherin) in qui-
escent ECs is crucial for cell–cell adhesion and optimal
endothelial barrier function, which are required for con-
trolled exchange of fluids and solutes between the blood-
stream and the neighboring tissue [64,65]. Lowering of pro-
angiogenic signals and increasing pro-quiescence mole-
cules promote ECs quiescence.
Metabolic signals
Less is known about the metabolic changes that precede or
accompany the EC’s switch to quiescence. Interestingly,
cell quiescence is often characterized by a higher level of
metabolism than previously anticipated [15]. Quiescent
ECs lower their glycolysis rate only by 40% – the propor-
tion of total glycolysis that is required for proliferation and
migration [8] (proliferation has been estimated to require a
30% increase in ATP production over quiescence [66]). The
remaining 60% of glycolysis in quiescent ECs ensures
Filopodia
Lamelipodia
Low High
Glycoly!c ac!vityMitochondria
Key:
Sprou!ng !p
Quiescent
(A) (B)
(C)
ATP
PK-M1
Tomm20
PK-M1
Tomm20
Ac!n
(D)
Nucleus Ac!n fiber
TRENDS in Endocrinology & Metabolism 
Figure 4. Compartmentalization of glycolysis with F-actin. (A) Schematic representation of a quiescent and a tip cell with mitochondria in the perinuclear region but, in the
case of the tip cell, not in filopodia or lamellipodia in which glycolytic activity is compartmentalized with F-actin. (B) Imaging of intracellular ATP levels in endothelial cells
(ECs) with a GO-Ateam ATP fluorescence resonance energy transfer (FRET) probe showing the presence of ATP in lamellipodia (white arrowheads). (C,D) Presence of
glycolytic activity in lamellipodia in the absence of mitochondria. EC double-stained for the glycolytic enzyme pyruvate kinase PK-M1 and the mitochondrial marker
Tomm20 (lamellipodia indicated by white arrowhead) (C) and merged with actin staining (D).
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cellular homeostasis and provides the necessary energy for
vital functions such as safeguarding barrier functions,
matrix deposition, and glycocalyx production [1,67]
(Figure 2D).
Concluding remarks and future perspectives
Over the past decade the angiogenesis field has gained an
enormous insight into the molecular players that control
the formation of vessels in physiological and pathological
conditions. Metabolism only recently entered the field of
angiogenesis as an important player. Although there are
some published data on the role of separate metabolic
pathways in ECs in vitro, a unifying view on how major
metabolic pathways converge in in vivo vessel branching is
almost nonexistent. Recent findings on how PFKFB3-driv-
en glycolysis determines vessel branching have only shown
the proverbial tip of the iceberg, and numerous outstand-
ing questions remain to be addressed (Box 1). For example,
a ‘metabolo-map’ of ECs in quiescence versus sprouting
state is largely missing, and other pathways besides gly-
colysis have been only minimally studied. Furthermore, it
is currently unknown how other branching signals (aside
from VEGF and Notch) control metabolism and vice versa.
The importance of metabolic communication between ECs
and other cell types, in normal tissues as well as in the
tumor microenvironment, remains unclear. In addition, it
is crucial to understand how the metabolic adaptations of
growing tumor vessels differ from those of rapidly prolif-
erating cancer cells because this will influence our thera-
peutic targeting strategies. Another outstanding question
is whether the definition of an underlying metabolic shift
that ECs undergo from quiescence to angiogenesis will
allow the development of new ‘anti metabolic anti angio-
genic’ agents, and whether targeting EC metabolism could
therefore provide a valuable alternative to overcome resis-
tance to currently approved anti angiogenic therapies,
without causing unacceptable toxicity. This is a timely
question given that novel anti angiogenic strategies with
fundamentally new mechanisms will likely aid in overcom-
ing toxicity and resistance issues of current anti angiogenic
therapies [3]. The generation of EC-specific metabolic
knockout animals, as well as the continuous improvement
of techniques to assess metabolic fluxes of ECs in quiescent
and growing vessels in vivo, will be required to answer all
these intriguing questions.
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Ectopic lipid deposition in muscle and liver is associated with the pathogenesis of type II diabetes. Hagberg
et al. (2012) report that targeting the vascular endothelial growth factor (VEGF)-B restores insulin sensitivity
and glucose tolerance by inhibiting endothelial-to-tissue lipid transport, opening promising avenues for
diabetes therapy.
Type II diabetes represents a formidable
unmet medical health problem with more
than 300 million people estimated to
be affected worldwide. Individuals with
diabetes have an elevated risk of vascular
disease (atherosclerosis, stroke) and
other complications. Diabetes-related
deaths are expected to rise at an alarming
speed over the coming years. Insulin
resistance has been linked to accumula-
tion of toxic lipid intermediates (ceram-
ides, diacylglycerol) in skeletal muscle
and liver. Hence, strategies prevent-
ing lipid deposition may offer therapeutic
benefit but are not widely available
(Samuel and Shulman, 2012). Hagberg
et al. (2012) demonstrate that targeting
the vascular endothelial growth factor B
(VEGF-B) restores insulin sensitivity and
prevents type II diabetes by reducing lipid
accumulation in muscle.
How can an angiogenic growth factor
like VEGF-B be linked to diabetes?
VEGF-B was one of the later members of
the VEGF family to be identified, and
its activity remains poorly understood
(Fischer et al., 2008). It is expressed in
the heart, skeletal muscle, and brown fat
and binds to VEGF receptor-1 (VEGFR1;
flt-1) and its coreceptor neuropilin-1
(NRP1). Genetic studies indicate that
VEGF-B’s angiogenic capacity is contex-
tual and largely restricted to the heart,
while pharmacological blockade inhibits
ocular angiogenesis. In cancer, VEGF-B
is, however, anti-angiogenic. Overall, its
activity is less potent than other traditional
angiogenic signals, but it induces strong
arterialization of the coronary vascula-
ture in rats (Bry et al., 2010). Importantly,
VEGF-B overexpression in mouse but
not in rat hearts leads to hypertrophy and
signs of mitochondrial lipotoxicity, sug-
gesting a possible role in cardiac metabo-
lism (Bry et al., 2010; Karpanen et al.,
2008). However, VEGF-B does not affect
mitochondrial function per se (Hagberg
et al., 2010; Karpanen et al., 2008). Rather,
it promotes lipid transport across the
endothelial barrier by upregulating the
fatty acid transport proteins (FATP)-
3/4 (Hagberg et al., 2010). Indeed, lipid
uptake and deposition in muscle were
reduced, and lipids were shunted to
white adipose tissue in VEGF-B-deficient
mice. Consequently, the fat mass and
body weight increased, and glucose
uptake to the heart was enhanced. These
initial observations prompted Hagberg
et al. (2012) to investigate the poten-
tial of anti-VEGF-B therapy for insulin
resistance.
In their follow-up study, Hagberg et al.
(2012) demonstrate that genetic defi-
ciency of VEGF-B in mouse models of
insulin resistance and type II diabetes,
including db/db diabetic mice (which
carry mutations in the leptin receptor
gene) andmice fedahigh-fat diet, reduces
lipid storage in muscle, heart, and
pancreas—but not liver. VEGF-B inhibi-
tion reduced plasma triglyceride and non-
esterified fatty acid levels and normalized
the HDL-c to LDL-c ratio, indicat-
ing a reduced risk for cardioavascular
pathology. However, the body weight of
VEGF-B-deficient mice on a high-fat diet
was increased. Nevertheless, VEGF-B
deficiency lowered blood glucose levels
without increasing insulin secretion and
restored insulin sensitivity and glucose
uptake in the muscle and heart.
Pharmacological inhibition of VEGF-B
via the administration of an anti-VEGF-B
antibody to db/db mice or rats fed a
high-fat diet largely phenocopied the
genetic findings and enhanced insulin
sensitivity. In a preventive setting (predia-
betic db/dbmice), VEGF-B blockade pre-
vented the development of hypergly-
cemia, reduced lipid uptake in muscle,
improved glucose tolerance, and pro-
tected against dyslipidemia. In a thera-
peutic setting (diabetic db/db mice),
VEGF-B inhibition halted the progres-
sion of hyperglycemia and muscle lipid
uptake. In addition, VEGF-B blockade
improved pancreatic islet morphology,
restored insulin and glucagon expression
in the islets, and reduced islet cell death
in both models. In another high-fat diet
rat model, coincident initiation of the
high-fat diet and anti-VEGF-B treat-
ment normalized glucose tolerance
and glucose-stimulated insulin secretion,
reduced glucose infusion and disposal
rates in a hyperinsulinemic/euglycemic
clamp study, and promoted glucose
uptake in muscle—evidence of improved
insulin sensitivity. These results support
the idea that VEGF-B regulates lipid
uptake by muscles. Given that VEGF-B
regulates lipid transport across the endo-
thelium, the findings suggest that the
endothelium acts as a prominent barrier
controlling muscle lipid uptake. Further-
more, blocking VEGF-B provides a mech-
anism to ameliorate or even prevent type
II diabetes (Figure 1).
As with any breakthrough, this study
raises a number of questions. For in-
stance, is the effect of VEGF-B on trans-
endothelial lipid transport the onlymecha-
nism? VEGF-B has a poor angiogenic
activity in healthy conditions, but an effect
of this growth factor on the vasculature
in conditions of insulin resistance remains
possible. Another question is whether
VEGF-B can control insulin signaling in
Cell Metabolism 16, November 7, 2012 ª2012 Elsevier Inc. 553
Cell Metabolism
Previews
endothelial cells, a process known to in-
crease insulin delivery to muscle (Kubota
et al., 2011). Since insulin also promotes
lipid uptake in muscle, VEGF-B’s activity
might also depend on effects on in-
sulin. It would also be interesting to test
whether endothelial deletion of NRP1 or
VEGFR1, known to reduce the levels of
the FATP4 transport protein in vitro
(Hagberg et al., 2010), phenocopies the
protective effects of VEGF-B blockade
in vivo. Given that different VEGF-B-
deficient mouse strains exhibit distinct
phenotypes in baseline conditions (Aase
et al., 2001; Bellomo et al., 2000), a con-
firmation of the antidiabetic phe-
notype in another VEGF-B-deficient strain
would strengthen the current findings. It
would also be interesting to explore if
VEGF-B has additional prodiabetic
effects through other changes in endothe-
lial cells, perhaps modifying endothelial
cell metabolism or endothelial-to-adipo-
cyte differentiation, or altering vascular
inflammation, a process known to modify
insulin sensitivity.
For anti-VEGF-B treatment to be clini-
cally relevant, the data of the Hagberg
et al. (2012) paper should be relevant
for humans. While the authors paid
great effort to test various rodent models,
genetic association studies have not
yet overwhelmingly identified VEGF-B as
a possible risk factor for diabetes in
humans. Another clinically relevant ques-
tion is whether therapeutic blockade
of VEGF-B therapy is safe. Deficiency of
VEGF-B is well tolerated. Nonetheless,
VEGF-B has been implicated in neuro-
genesis and neuroprotection (Poesen
et al., 2008) and ischemic cardiac re-
vascularization, raising the question
whether VEGF-B blockade might worsen
diabetic neuropathy or ischemic heart
disease. The role of VEGF-B in in-
hibiting tumor angiogenesis will also
deserve consideration. Overall, this work
places the endothelium and its regula-
tion by the VEGF-B ligand at the center
stage of tissue lipid homeostasis,
with promising therapeutic potential in
the context of diabetes, obesity, and
dyslipidemia.
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Pancreatic b cell failure is central in the pathogenesis of type 2 diabetes (T2D), but the mechanisms involved
remain unclear. Mahdi and colleagues (2012) couple global evaluation of gene expression with coexpression
network analysis of human islets from T2D patients to identify SFRP4 as an early mediator of b cell dysfunc-
tion in T2D.
Genome-wide association studies for
T2D have so far identified 65 susceptibility
loci for the disease (Morris et al., 2012),
but together these loci account for less
than 10% of the variance in disease
susceptibility. This contrasts with the situ-
ation in type 1 diabetes (T1D), where such
studies have identified 50 loci across the
human genome associated with T1D that
explain nearly 80% of the heritability
(Pociot et al., 2010). Other approaches
to identify basic mechanisms of disease
are therefore needed (Taneera et al.,
2012). Furthermore, direct studies of the
diseased human tissue—in the case of
T2D, human islets are the gold standard
given the central role of b cell dysfunc-
tion in its pathogenesis—are essential to
further our understanding of human dia-
betes (Cnop et al., 2005; Kahn, 2003). In
this issue of Cell Metabolism, Mahdi and
colleagues tackle these challenges by
performing microarray analyses of human
islets isolated from T2D and normoglyce-
mic individuals (Mahdi et al., 2012) (Fig-
ure 1). They identify a group of T2D-
associated genes related to interleukin-1
(IL-1), a proinflammatory cytokine, and
show that secreted frizzled-related pro-
tein 4 (SFRP4) is highly associated
with T2D.
Previous work already suggested that
IL-1b plays a role in b cell dysfunction
and death in T1D and T2D. However,
whereas a role for inflammation in b cell
loss is well established in the context of
T1D (Eizirik et al., 2009), it has remained
controversial for T2D (Cnop et al., 2005;
Donath et al., 2008). To explain local
IL-1b production in the islets of T2D indi-
viduals, one model proposed that IL-1b
production was induced by glucose,
leading to upregulation of the apoptotic
Fas receptor and ligand and b cell
‘‘suicide’’ (Donath et al., 2008), but this
was not confirmed by other groups (re-
viewed in Cnop et al., 2005). In recent
years a more nuanced view of inflamma-
tion in T2D islets emerged, consisting
of mild upregulation of cytokines and
chemokines in islets from T2D patients,
possibly mediated by increased circu-
lating concentrations of the free fatty
acid palmitate that induces islet IL-1b
and TNF-a expression (Igoillo-Esteve
et al., 2010). Experimental findings show
that this metabolic ‘‘T2D-like’’ stress
induces a mild inflammatory response,
representing around 5%–10% of the pro-
inflammatory response of human islets
exposed to ‘‘T1D-like’’ conditions (Cnop
et al., 2005; Igoillo-Esteve et al., 2010).
The role for this ‘‘low-intensity’’ innate
immunity-mediated inflammation in b cell
dysfunction and death in T2D remains
unclear. For instance, an IL-1 receptor
antagonist blocked palmitate-induced
chemokine expression, but failed to pre-
vent apoptosis (Igoillo-Esteve et al., 2010).
Using gene expression topology with
weighted gene coexpression network
analysis (in which coexpressed genes
are clustered into gene modules based
on their connectivity), Mahdi et al. now
identify a T2D-related gene module en-
riched for IL-1-related genes. Among the
most connected hub genes, the authors
identify SFRP4 as highly associated with
T2D, HbA1c (a measure of average
glucose levels over the past 2 months),
and insulin secretion (Figure 1). Subse-
quent functional studies then show that
the SFRP4 protein is induced by the cyto-
kine IL-1b. Furthermore, the authors show
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